The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Level Of Market Value Growth Is Predicted For The Chlamydia Infection Diagnostics Market From 2026 To 2030?
The chlamydia infection diagnostics market size has seen swift expansion in recent years. It is forecast to grow from $1.4 billion in 2025 to $1.56 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.5%. This historic growth can be attributed to several factors, including the expansion of laboratory infrastructure, an increasing incidence of chlamydia infections, the enhanced utilization of molecular diagnostics, a rise in clinical testing volumes, and the availability of standardized diagnostic protocols.
The chlamydia infection diagnostics market is poised for significant expansion over the coming years. Projections indicate it will reach a value of $2.39 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.3%. This anticipated growth is driven by several factors, including a heightened demand for swift and automated diagnostic solutions, increased capital allocation towards laboratory automation, the proliferation of decentralized diagnostic testing, an intensified emphasis on detecting infections early, and ongoing advancements in molecular testing technologies. Key trends anticipated during this period encompass the wider implementation of sophisticated molecular diagnostic platforms, a growing uptake of PCR and LAMP-based testing methods, the deeper integration of automation within diagnostic laboratories, an expansion of capabilities for high-throughput screening, and a stronger emphasis on both the precision and rapidity of diagnostics.
Access Your Free Sample Report For In-Depth Market Analysis:
What Leading Drivers Are Supporting The Chlamydia Infection Diagnostics Market Expansion?
The increasing emphasis on preventive healthcare is projected to boost the chlamydia infection diagnostics market in the future. Preventive healthcare encompasses steps taken to avert illnesses instead of treating them post-occurrence, utilizing methods such as routine examinations, immunizations, and lifestyle adjustments. This heightened focus on preventive healthcare seeks to lower medical expenses, enhance overall quality of life, and prevent chronic disease development via early identification and proactive health strategies. Preventive care is vital for chlamydia diagnostics as it promotes early detection, public awareness, and consistent screening, all of which contribute to curbing the transmission and adverse effects of chlamydia infections. For example, in May 2023, data from the National Health Service (NHS), a publicly funded healthcare provider in the UK, indicated that approximately 23.02 million diagnostic tests were performed in March 2023, showing an increase of 223,100 tests compared to March 2022. Additionally, in March 2023, the count of individuals awaiting a vital diagnostic test reached 16.28 million, an increment of 59,400 from March 2022. Consequently, the rising prioritization of preventive healthcare fuels expansion in the chlamydia infection diagnostics market.
How Is The Chlamydia Infection Diagnostics Market Organized By Segment Classification?
The chlamydia infection diagnostics market covered in this report is segmented –
1) By Test Type: Culture Test, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Test, Other Test Types
2) By Type Of Infections: Genital Chlamydia Infection, Rectal Chlamydia Infection, Ocular Chlamydia Infection
3) By Application: Hospitals, Specialty Clinics, Diagnostic Centers
4) By End User: Diagnostics, Therapeutics
Subsegments:
1) By Culture Test: Cell Culture, Egg Culture
2) By Nucleic Acid Amplification Test (NAAT): PCR-Based Test, LAMP-Based Test
3) By Direct Fluorescent Antibody Test: Direct Fluorescent Antibody Staining, Direct Fluorescent In-Situ Hybridization
4) By Serology Test: Immunoassays, Enzyme Immunoassay (EIA)
5) By Other Test Types: Enzyme-Linked Immunosorbent Assay (ELISA), Hybrid Capture Test
What Emerging Trends Are Seen In The Chlamydia Infection Diagnostics Market?
Leading companies in the chlamydia infection diagnostic market are focusing on creating advanced products, such as molecular point-of-care testing platforms, to achieve a competitive advantage. These molecular point-of-care (POC) testing platforms are diagnostic instruments designed to identify and analyze specific nucleic acids (DNA or RNA) of pathogens directly at the patient care location. For example, in May 2024, Sherlock Biosciences, a US based biotech company, revealed the development of its Sherlock test, which stands as one of the initial molecular disposable tests for Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG). The outcomes of this diagnostic test are available in under 30-minutes through the analysis of DNA and RNA gathered from self-collected penile meatal or vaginal swabs.
Who Are The Industry Participants Involved In The Chlamydia Infection Diagnostics Market?
Major companies operating in the chlamydia infection diagnostics market are Roche Diagnostics, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers, Becton, Dickinson and Company, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Hologic Inc., Illumina Inc., bioMérieux SA, QuidelOrtho Corporation, Bio-Rad Laboratories, Inc., Qiagen N.V., DiaSorin S.p.A., Randox Laboratories Ltd., Cepheid, Meridian Bioscience Inc., Sekisui Diagnostics, Copan Diagnostics
Get The Full Chlamydia Infection Diagnostics Market Report:
Which Region Leads The Chlamydia Infection Diagnostics Market In Terms Of Market Share?
North America was the largest region in the chlamydia infection diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chlamydia infection diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Chlamydia Infection Diagnostics Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Chlamydia Infection Diagnostics Market 2026, By The Business Research Company
Chlamydia Infection Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/chlamydia-infection-treatment-global-market-report
Chlamydia Infection Diagnostics And Therapeutics Market Report 2026
Chlamydia Trachomatis Ct And Neisseria Gonorrhoeae Ng Testing Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model